First-line treatment with/without extended (maintenance) treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
Maintenance after first-line therapy: Treatment to prevent relapse after complete response to therapy
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
First-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Drug Class | Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|---|
| Standard of Care Targeted Drugs | |||||
| Angiogenesis Inhibitors: VEGF | NCT00262847; GOG-218 | III | Bevacizumab, Carboplatin, Paclitaxel Prescribing Information | A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG218) | Improved PFS with addition of bevacizumab to carboplatin+paclitaxel in high risk patients, particularly those with ascites CarboPt+Pac+Bev w/ Bev maint vs CarboPt+Pac+Bev vs CarboPt+Pac: All: pub 2015; abs Jun 2018 |
| Angiogenesis Inhibitors: VEGF | NCT00483782; ICON7 | III | Bevacizumab, Carboplatin, Paclitaxel Prescribing Information | ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer | Improved PFS and OS with addition of bevacizumab to carboplatin+paclitaxel in high risk patients CarboPt+Pac+Bev w/ Bev maint vs CarboPt+Pac: All: pub 2011; 2015 |
| Angiogenesis Inhibitors: VEGF | NCT00951496; GOG-252 | III | Bevacizumab, Carboplatin, Cisplatin, Paclitaxel | A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | Compared to the IV reference arm, PFS was not significantly increased with either IP regimen IV CarboPt+Pac+Bev w/ Bev maint vs IP CarboPt+Pac+Bev w/ Bev maint vs IP CisPt+Pac+Bev w/ Bev maint: PFS: 24.9 vs 27.4 vs 26.2 months pub 2019 |
Maintenance after first-line therapy: Treatment to prevent relapse after complete response to therapy
For more detailed information, please click on the clinical trial ID number.
| Drug Class | Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|---|
| Standard of Care Targeted Drugs | |||||
| DNA Damage Repair Pathway Inhibitors:PARP | NCT01844986; SOLO-1 | III | Olaparib Prescribing Information | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy (SOLO-1) | Considerably improved PFS for BRCA MUT patients with olaparib maintenance treatment Ola maint vs Placebo: PFS: Not Reached vs 14.1 months* pub 2018 |
| Drugs in NCCN Guidelines | |||||
| Chemotherapy | NCT00003120; GOG-178 | III | Paclitaxel | Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy (GOG-178) | Improved PFS with 12 cycles of paclitaxel, no OS difference 12 cycles Pac vs 3 cycles Pac: PFS: 28 vs 21 months* pub 2003; 2009 |
| Drugs in Clinical Development | |||||
| Chemotherapy | NCT00108745 | III | Paclitaxel, Paclitaxel Poliglumex | A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy | Improved PFS with paclitaxel poliglumex or paclitaxel maintenance treatment, but no OS difference Pac Poliglu vs Pac vs Placebo: PFS: 16.3 vs 18.9 vs 13.4 months* abs Mar 2017 |
| Hormonal Therapy: Aromatase | Letrozole University Hospital Basel | Single-site | Letrozole | Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients | Promising activity with minimal toxicity of letrozole maintenance in ER-positive patients Let vs Placebo: All patients: Patients w/o residual disease: Patients w/ residual disease: pub 2018 |
| Hormonal Therapy: Aromatase | Retrospective Study: Hormonal Maintenance in LGSC | II | Anastrozole, Letrozole, Tamoxifen | Retrospective analysis of Hormonal Maintenance Therapy for Patients With LGS Ovarian Cancer | Significantly longer PFS with hormonal maintenance therapy (HMT) vs. observation (OBS) in Low Grade Serous OC patients HMT vs OBS: PFS: 64.9 vs 26.4 months pub 2017 |
| Hormonal Therapy: Anti-Estrogens | Retrospective Study: Hormonal Maintenance in LGSC | II | Anastrozole, Letrozole, Tamoxifen | Retrospective analysis of Hormonal Maintenance Therapy for Patients With LGS Ovarian Cancer | Significantly longer PFS with hormonal maintenance therapy (HMT) vs. observation (OBS) in Low Grade Serous OC patients HMT vs OBS: PFS: 64.9 vs 26.4 months pub 2017 |
| Immunotherapy: Vaccine | NCT01309230 | II | Gemogenovatucel-T | Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer | FANG vaccine shows encouraging anti-tumor activity and increased RFS with remarkable safety FANG vs Placebo: RFS (from time of procurement, mean/median): pub 2016 |